Home
About
Overview
Sharing Data
ORCID
Help
History (67)
Preliminary acute and subchronic toxicity studies of GLG-V-13, a novel class III antiarrhythmic agent, in mice.
Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
Atrial fibrillation in obstructive sleep apnea: Neural mechanisms and emerging therapies.
When nerves go awry: The multiple ways to treat atrial fibrillation.
Antiarrhythmic effects of vasostatin-1 in a canine model of atrial fibrillation.
See All 67 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Antiarrhythmic effects of vasostatin-1 in a canine model of atrial fibrillation.
Antiarrhythmic effects of vasostatin-1 in a canine model of atrial fibrillation. J Cardiovasc Electrophysiol. 2012 Jul; 23(7):771-7.
View in:
PubMed
subject areas
Acetylcholine
Action Potentials
Animals
Anti-Arrhythmia Agents
Atrial Fibrillation
Cardiac Pacing, Artificial
Chromogranin A
Disease Models, Animal
Dogs
Dose-Response Relationship, Drug
Electrocardiography
Electrophysiologic Techniques, Cardiac
Ganglia, Autonomic
Humans
Male
Peptide Fragments
Refractory Period, Electrophysiological
Time Factors
authors with profiles
Benjamin J Scherlag
Stavros Stavrakis
Sunny S Po